GLP-1 Dosing and Titration: How the Schedule Actually Works

Nobody starts a GLP-1 at the dose that produces the headline weight-loss number. Every approved product ramps up gradually over months, and the schedule isn't arbitrary — it's the main tool prescribers have to blunt the gastrointestinal side effects covered in GLP-1 side effects: what the STEP and SURMOUNT trials actually reported. Here's how the actual titration works, per current FDA-approved labeling.

Titration is a floor, not a race

It's worth being explicit about what the schedule is and isn't. The 4-week minimum between increases in every one of these labels is a floor, not a target — nothing in the labeling requires you to step up the moment you're eligible. If a dose is working and you're tolerating it well, staying at a lower rung longer than the minimum is a legitimate, common approach many prescribers use, not a sign something has gone wrong. Titration exists to protect you from moving too fast; it isn't a countdown you're expected to race through.

Why titration exists at all

GLP-1 receptor agonists cause nausea, vomiting, and diarrhea largely as a function of dose and how quickly the dose increases. Starting at a low dose and stepping up slowly gives your digestive system time to adjust before the next increase. Skip or rush this and you're more likely to feel it. This is also why a compressed, "fast-track" titration offered by a discount program is worth scrutinizing rather than assuming it's a bonus — slower is usually more tolerable, not slower for its own sake.

Wegovy (semaglutide) injection

Per the current label, the injection titrates on a four-week cadence¹:

| Weeks | Dose | |---|---| | 1–4 | 0.25 mg | | 5–8 | 0.5 mg | | 9–12 | 1 mg | | 13–16 | 1.7 mg | | 17+ | 2.4 mg (maintenance) |

That's roughly four months before reaching the studied maintenance dose used in the STEP trials.

Wegovy (semaglutide) tablet

The oral tablet formulation, approved more recently, titrates on a monthly cadence measured in days rather than weeks¹:

| Days | Dose | |---|---| | 1–30 | 1.5 mg | | 31–60 | 4 mg | | 61–90 | 9 mg | | 91+ | 25 mg (maintenance) |

Note that tablet and injection doses aren't directly comparable milligram-for-milligram — they're different formulations with different absorption, so "25 mg tablet" isn't a higher dose than "2.4 mg injection" in any meaningful sense. For how the trial evidence for oral and injectable formulations compares, see oral GLP-1 pills vs injections: what the trial evidence shows.

Ozempic (semaglutide) injection

Ozempic's label uses the same molecule as Wegovy injection but a different dosing track, approved for type 2 diabetes: start at 0.25 mg once weekly, increase to 0.5 mg after 4 weeks, then step up at 4-week intervals toward a maximum of 2 mg once weekly; patients with chronic kidney disease titrate to a 1 mg maintenance dose after 4 weeks at 0.5 mg².

Mounjaro and Zepbound (tirzepatide)

Both tirzepatide products — Mounjaro (type 2 diabetes) and Zepbound (weight management) — start at 2.5 mg injected once weekly for 4 weeks, a dose the label notes is intended for treatment initiation and isn't effective for glycemic control or meaningful weight loss on its own³⁴. After 4 weeks, the dose increases to 5 mg once weekly, then can increase further in 2.5 mg increments after at least 4 weeks at the current dose, up to a maximum of 15 mg weekly. Zepbound's maintenance range for weight reduction is 5 mg, 10 mg, or 15 mg once weekly⁴.

Special populations get a different track

Titration isn't one-size-fits-all even within a single product. Ozempic's label carries a modified track for patients with chronic kidney disease, capping the maintenance dose at 1 mg rather than pushing toward the standard 2 mg ceiling². Mounjaro's label sets a lower maximum for pediatric patients 10 years and older — 10 mg weekly rather than the 15 mg adult ceiling³. And Zepbound's maintenance range actually depends on which indication you're being treated for: 5 mg, 10 mg, or 15 mg for weight reduction, but only 10 mg or 15 mg for its obstructive sleep apnea indication⁴. None of this is something a generic dosing chart captures — it's a reason the person managing your titration needs your actual medical history, not just your weight.

The common thread

Across every approved GLP-1, the pattern is the same: a low starting dose, increases no more often than every 4 weeks, and a maintenance dose that typically isn't reached for 2–5 months depending on the product. If a provider proposes skipping steps or compressing the schedule outside this framework, ask why — and ask what happens to your risk of nausea and vomiting if they do. A program that follows the labeled titration and adjusts pace based on how you're tolerating it is doing the job correctly; that kind of medical judgment is exactly what we weigh in our Value Score methodology alongside price.

Comparing programs on more than price

Once you know what a normal titration should look like, you can evaluate whether a program's medical process matches it. Compare pricing across the full titration period — not just the starting-dose month — on our semaglutide and tirzepatide boards, and check how each program handles dose adjustments in our provider reviews.

This piece sits in our research index alongside every other sourced explainer we publish — the trials, the compounding rules and the pricing mechanics, grouped by the question each one answers.